Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10396804" target="_blank" >RIV/00064165:_____/19:10396804 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/19:10396804

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwkXmG2qFg" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwkXmG2qFg</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amgh201932" target="_blank" >10.14735/amgh201932</a>

Result language

angličtina

Original language name

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Original language description

Background: Data about the usefulness of monitoring vedolizumab therapy are sparse and conflicting. Here, the aim was to assess the association between early vedolizumab trough levels (VTLs) and responses to induction therapy in patients with inflammatory bowel disease (IBD). Methods: The study population comprised consecutive IBD patients from a prospective cohort of vedolizumab treated individuals at our centre, in whom VTLs and anti-vedolizumab antibodies (AVAs) were measured during the induction phase of therapy. Included patients received vedolizumab (300 mg) at weeks 0, 2 and 6, with an extra dose at week 10 in cases of inadequate response after the third infusion. Clinical response was evaluated by a physician at 1 month after the last induction dose (week 10 or 14). Measurement of VTL and AVA was performed by ELISA. Results: Eighty-seven patients, 31 with Crohn&apos;s disease and 56 with ulcerative colitis, were included. Only 15% of patients were naïve to anti-tumour necrosis factor alpha therapy; 61% used concomitant systemic steroids and 26% used thiopurines. An additional dose at week 10 was given to 39% of individuals. Clinical response to induction was reported in 77% of IBD patients. The median VTL at week 6 was 30.6 µg/mL (range: 1.1-80.0). When comparing patients with and without a clinical response to vedolizumab, we found no significant difference in the median VTL at week 6 (29.4 vs. 34.4 µg/mL, respectively; p = 0.71). Likewise, VTL did not differ significantly between individuals receiving an additional dose at week 10 and those receiving standard induction (40.0 vs. 28.5, respectively; p = 0.69). Seven per cent of patients developed positive AVA up until weeks 10-14. Diagnosis type, concomitant immunosuppressants or previous biologic therapy had no impact on VTL. Conclusion: There was no association between early VTL and clinical response to induction therapy. Further studies should address the clinical relevance of therapeutic drug monitoring during long-term vedolizumab treatment.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Gastroenterologie a hepatologie

ISSN

1804-7874

e-ISSN

—

Volume of the periodical

73

Issue of the periodical within the volume

1

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

5

Pages from-to

32-36

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85065545305